Mortality due to cervical cancer can be reduced by prevention, early detection & treatment.
Vaccination may be started as early as 9 years old.
Vaccination may reduce the incidence of HPV-related disease.
Screening for cervical cancer after vaccination is still recommended because only 70% of the virus types associated w/ invasive cervical cancer consist of HPV 16 & 18 types & women may not be entirely protected if they have been infected w/ other HPV types prior to vaccination.
It appears that women who tend to avoid Pap smear screening in Singapore are those who are younger, of Malay ethnicity and who lack confidence in the effectiveness of the procedure as a prevention measure against cervical cancer, a study reports.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
Endocervical sampling with a new fabric-based curette device reduces the number of “inadequate” specimens and hence, the need for repeat biopsies compared with conventional metal scraping, reveals a recent study.
Dr Ravichandran Nadarajah, a consultant at the Department of Obstetrics & Gynaecology, Singapore General Hospital, speaks to Roshini Claire Anthony on the importance of early diagnosis and prevention of cervical cancer.
The addition of bevacizumab to chemotherapy improved overall survival (OS) in women with metastatic, persistent, or recurrent cervical cancer, according to the final OS analysis of the Gynecologic Oncology Group (GOG) 240 trial, confirming the findings observed in the interim analysis.
Dr Ravichandran Nadarajah, a consultant at the Department of Obstetrics & Gynaecology, Singapore General Hospital, speaks to Roshini Claire Anthony on the significant role played by GPs in ensuring early diagnosis and prevention of cervical cancer.
Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving ≥2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.